Insight Resource Library Tap into Gubra’s vast production of publications, webinars, videos and posters to get the latest knowledge and insights within our focus areas: obesity, diabetes, MASH, CKD, IPF and IBD. Filtered (29) Filters Reset all × db/db mouse × GIP receptor agonist × GLP-2 receptor × GUB09-145 × Pharmacokinetics × Rosiglitazone × siRNA × Search × Resource type Data presentation (0) Poster (3) Publication (25) 3D imaging video (0) Webinar (1) Category × Disease model (223) Cardiovascular disease (11) AngII mouse (2) DIO-ApoE-KO mouse (1) DIO-LDLR-KO mouse (4) DIO-PCK9-AAV mouse (1) Isoprenaline-induced cardiomyopathy (1) Cholangiopathy (1) Bile duct ligation (BDL) mouse (1) Mdr2-KO mouse (1) CNS disease (39) Alzheimer's disease models (9) CNS activation (12) Drug distribution (6) Gene expression (1) Gene therapy (1) Parkinson's disease models (6) Diabetes (33) db/db mouse (17) Non-obese diabetic (NOD) mouse (4) ZDF rat (10) Inflammatory bowel disease (3) Acute DSS-IBD mouse (0) Chronic DSS-IBD mouse (3) Idiopathic pulmonary fibrosis (7) BLEO-IPF mouse (4) Chronic BLEO-IPF mouse (2) HFD-BLEO-IPF mouse (0) Kidney disease (33) Acute kidney injury (4) Bilateral ischemia reperfusion injury (bIRI) mouse (1) Unilateral ischemia reperfusion injury (uIRI) mouse (3) Chronic kidney disease (18) Anti-GBM glomerulonephritis mouse (2) Adenine diet-induced (ADI) nephropathy mouse (5) Polycystic kidney disease (PCK) rat (1) Unilateral ureteral obstruction (UUO) mouse (4) 5/6 nephrectomy (Nx) rat (3) Diabetic kidney disease (17) db/db-UNx mouse (1) ReninAAV UNx db/db mouse (11) ZSF-1 rat (0) Knock-out mouse models (8) Metabolic dysfunction-associated steatohepatitis (76) GAN DIO-MASH mouse (30) GAN DIO-MASH-HCC mouse (8) GAN ob/ob-MASH mouse (5) CDAA-HFD mouse (9) CDAA-HFD rat (10) AMLN DIO-MASH mouse (18) AMLN ob/ob-MASH mouse (13) Obesity (52) Bariatric surgery (10) DIO mouse (23) DIO rat (14) ob/ob mouse (8) Therapeutic Area (242) Alzheimer's disease (13) Alcoholic steatohepatitis (2) Cardiovascular disease (10) Chronic kidney disease (28) Cholangiopathy (1) Diabetes (55) Diabetic cardiomyopathy (2) Diabetic kidney disease (18) Hepatocellular carcinoma (6) Idiopathic pulmonary fibrosis (7) Inflammatory bowel disease (3) Metabolic dysfunction-associated steatohepatitis (84) Obesity (81) Parkinson's disease (8) Target (149) Alpha-synuclein (1) Autotaxin (1) Beta amyloid (4) Acetyl-CoA carboxylase (2) Amylin receptor (4) Angiotensin converting enzyme (ACE) (5) AMPK (1) ASBT (2) CB1 receptor (5) CCK receptor (4) D2 receptor (3) DPP-IV (2) Fatty acid synthase (1) FGF receptor-1 (3) FXR (12) GCC receptor (1) GFRAL (1) Ghrelin receptor (3) GIP receptor (5) GLP-1 receptor (73) GLP-2 receptor (5) Glucagon receptor (5) GPR119 (0) GPR120 (1) G-protein coupled receptor 10 (GPR10) (1) HSD17b13 (1) 5-HT2C receptor (3) IL-1beta receptor (1) Insulin receptor (2) mARC1 (1) MC4 receptor (4) Monoamine transporter (2) Leptin receptor (1) Neuropeptide FF receptor type 2 (1) Neurotensin receptor (1) Nicotinic acetylcholine receptor (1) NPY receptor (2) NMU receptor (2) Paraoxonase-2 (1) PCSK9 (1) PICK1 (1) PPAR (22) PSD-95 (1) Renin–angiotensin system (3) Secretin receptor (1) SGLT-2 (5) TAAR1 (1) TGF-beta (7) TGR5 (2) THR-ß receptor (5) Y2 receptor (3) Compound (146) Aducanumab biosimilar (4) Adeno-associated virus (AAV)-mediated gene therapy (1) A3907 (2) Adrenomedullin (2) Alk5 inhibitor (6) ALT-801 (1) Amylin (3) Amylin receptor agonist (1) BLD-0409 (1) Bromocriptine (2) CHS-131 (1) Captopril (1) Cilofexor (1) Cotadutide (1) DA-1241 (1) Dapagliflozin (2) Dietary intervention (4) Exenatide (9) Elafibranor (9) Empagliflozin (4) Exendin-4 analogues (3) FGF21 (3) Firsocostat (2) GDF15 analogues (1) Ghrelin (1) GIP receptor agonist (1) GIPRA (1) GIP receptor antagonist (1) Glibenclamide (1) GLP-1 (5) GLP-1 receptor agonist (5) GLP-2 (1) Glucagon receptor agonist (1) Glucose-dependent insulinotropic polypeptide (GIP) (1) Guanylin (1) GUB06-046 (1) GUB08-248 (1) GUB09-123 (1) GUB09-145 (2) GUB08251 (1) GUB021794 (1) GUBamy (1) GS-834356 (1) HSD17b13 inhibitor (1) HSG4113 (1) Icosabutate (1) ID166 (0) Insulin (1) INT-767 (4) INT-787 (0) Lanifibranor (9) LEAP-2 (2) Leptin (1) Linagliptin (5) Liraglutide (30) Lisinopril (5) Lorcaserin (3) MEDI0382 (1) mPD95 (1) Neuromedin U (2) Neurotensin (1) Neurturin (1) Nicotine (1) Obeticholic acid (10) Oxyntomodulin (1) PYY3-36 (4) Prolactin-releasing peptide (1) Resmetirom (6) Rimonabant (4) Rosiglitazone (2) S961 (1) Salmon calcitonin (1) SEFA-1024 (1) Seladelpar (2) Semaglutide (31) SER140 (1) Setmelanotide (3) Sibutramine (4) TAAR1 agonists (1) Taspoglutide (1) Teduglutide (2) Tirzepatide (1) TVB-3664 (1) UCCB01-147 (1) Uroguanylin (1) Vutiglabridin (1) Y2 receptor agonist (1) ZP3022 (3) Method/Endpoint (265) 3D imaging (57) Adeno-associated virus (AAV)-mediated gene delivery (14) Atherosclerotic plaques (3) Beta-cell mass (12) Blood pressure (1) Body composition (11) Body weight (123) Blood biochemistry (84) Bariatric surgery (12) Bioinformatics (105) c-Fos activation (19) Clinical trial (2) Conditioned taste aversion test (1) Drug discovery (25) Drug distribution (11) Energy expenditure monitoring (4) Echocardiography (ECG) (3) Flow cytometry (1) Gut biopsy (6) Glomerular filtration rate (GFR) (8) Gastric emptying (3) Gut morphometry (12) Glucose-stimulated insulin secretion (GSIS) (1) Histopathology score (79) Heart morphometry (5) Intraperitoneal glucose tolerance test (IPGTT) (7) Image analysis (150) Immunohistochemistry (IHC) (145) In situ hybridization (ISH) (14) Insulin tolerance test (ITT) (2) Kidney biopsy (2) Kidney morphometry (24) Lung functional test (5) Light sheet fluorescence microscopy (LSFM) (60) Liver biopsy (67) Liver morphometry (65) Lung biochemistry (4) Laser-capture microdissection (LCM) (9) Magnetic resonance imaging (MRI) (2) Microbiomics (5) Micro-computed tomography (micro-CT) (1) Neurobehavior (6) Next-generation sequencing (49) Nephrectomy (14) Oral glucose tolerance test (OGTT) (20) Pancreatectomy (1) Peptide chemistry (14) Pharmacokinetics (9) Proteomics (1) qPCR (1) Real-time food intake/activity analysis (32) Receptor binding (3) Roux-en-Y gastric bypass (RYGB) (8) RNA sequencing (84) Single-cell RNA sequencing (3) Single-nucleus RNA sequencing (6) siRNA (1) StreaMLine (1) Surgery (12) Spirometry (5) Stereology (29) Stereotaxic injection (2) Ultrasound imaging (1) Urine biochemistry (12) Vasculature (2) Vertical sleeve gastrectomy (1) Western Blotting (1) Whole-body plethysmography (4) Whole-brain in situ hybridization (4) Species (219) Hamster (1) Human (29) Mouse (177) Minipig (2) Non-human primate (3) Pig (3) Rat (34) Show (29) Cancel Sort result Default sorting By title: alphabetical By title: reverse By date: oldest first By date: newest first Reset all × db/db mouse × GIP receptor agonist × GLP-2 receptor × GUB09-145 × Pharmacokinetics × Rosiglitazone × siRNA × 29 resource library items found PosterPharmacokinetics of a long-acting GLP-1 receptor agonist in minipigs PublicationHepatocyte mARC1 promotes fatty liver disease PosterNephroprotective effects of semaglutide in a mouse model of hypertension-accelerated diabetic kidney disease PosterNephroprotective effects of standard of care in a state-of-the-art mouse model of hypertension-accelerated diabetic kidney disease WebinarImaging diabetes using light sheet microscopy PublicationLipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect PublicationPeptide-YY3-36/glucagon-like peptide-1 combination treatment of obese-diabetic mice improves insulin sensitivity associated with recovered pancreatic ß-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries PublicationTherapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease PublicationCharacterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in db/db mice Publication3D quantification of changes in pancreatic islets in mouse models of diabetes type I and II PublicationAutomated image analyses of glomerular hypertrophy in a mouse model of diabetic nephropathy PublicationIncretin combination therapy for the treatment of non-alcoholic steatohepatitis PublicationImpact of sex on diabetic nephropathy and the renal transcriptome in UNx db/db C57BLKS mice PublicationMetabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice PublicationAnimal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development PublicationPancreatic β-cell rest replenishes insulin secretory capacity and attenuates diabetes in an extreme model of obese type 2 diabetes PublicationNovel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice PublicationChemical Strategies for Half-life Extension of Biopharmaceuticals: Lipidation and its Alternatives PublicationGUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice PublicationPeptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues PublicationA hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist PublicationThe endogenous preproglucagon system is not essential for gut growth homeostasis in mice PublicationNeoglycolipids for prolonging the effects of peptides: Self-assembling glucagon-like peptide 1 analogues with albumin binding properties and potent in vivo efficacy PublicationRapid gut growth but persistent delay in digestive function in the postnatal period of preterm pigs Load More For further information Contact us Gubra Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650